KR101363830B1 - Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물 - Google Patents

Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물 Download PDF

Info

Publication number
KR101363830B1
KR101363830B1 KR1020127012498A KR20127012498A KR101363830B1 KR 101363830 B1 KR101363830 B1 KR 101363830B1 KR 1020127012498 A KR1020127012498 A KR 1020127012498A KR 20127012498 A KR20127012498 A KR 20127012498A KR 101363830 B1 KR101363830 B1 KR 101363830B1
Authority
KR
South Korea
Prior art keywords
methyl
mmol
pyran
chloro
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127012498A
Other languages
English (en)
Korean (ko)
Other versions
KR20130026523A (ko
Inventor
안나 벨렌 베니토 콜라도
누리아 디아즈 부에조
알마 마리아 지메네즈-아구아도
셀리아 라푸엔테 블랑코
마리아 안젤레스 마르티네즈-그라우
콘셉시온 페드레갈-테르세로
미구엘 앤젤 톨레도 에스크리바노
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20130026523A publication Critical patent/KR20130026523A/ko
Application granted granted Critical
Publication of KR101363830B1 publication Critical patent/KR101363830B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020127012498A 2009-11-16 2010-11-10 Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물 Expired - Fee Related KR101363830B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382246.8 2009-11-16
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27
US61/298,629 2010-01-27
PCT/US2010/056180 WO2011060035A1 (en) 2009-11-16 2010-11-10 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (2)

Publication Number Publication Date
KR20130026523A KR20130026523A (ko) 2013-03-13
KR101363830B1 true KR101363830B1 (ko) 2014-02-14

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127012498A Expired - Fee Related KR101363830B1 (ko) 2009-11-16 2010-11-10 Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물

Country Status (34)

Country Link
US (1) US8232289B2 (enExample)
EP (1) EP2501703B1 (enExample)
JP (1) JP5680101B2 (enExample)
KR (1) KR101363830B1 (enExample)
CN (1) CN102612520B (enExample)
AR (1) AR078863A1 (enExample)
AU (1) AU2010319581C1 (enExample)
CA (1) CA2796161C (enExample)
CO (1) CO6541545A2 (enExample)
CR (1) CR20130087A (enExample)
DK (1) DK2501703T3 (enExample)
DO (1) DOP2012000135A (enExample)
EA (1) EA020848B1 (enExample)
EC (1) ECSP12011902A (enExample)
ES (1) ES2435814T3 (enExample)
HN (1) HN2012001011A (enExample)
HR (1) HRP20130967T1 (enExample)
IL (1) IL219370A (enExample)
JO (1) JO2887B1 (enExample)
MA (1) MA33751B1 (enExample)
ME (1) ME01537B (enExample)
MX (1) MX2012005691A (enExample)
MY (1) MY160665A (enExample)
NZ (1) NZ600006A (enExample)
PE (1) PE20121430A1 (enExample)
PH (1) PH12012500969A1 (enExample)
PL (1) PL2501703T3 (enExample)
PT (1) PT2501703E (enExample)
RS (1) RS53018B (enExample)
SI (1) SI2501703T1 (enExample)
TW (1) TWI465453B (enExample)
UA (1) UA107943C2 (enExample)
WO (1) WO2011060035A1 (enExample)
ZA (1) ZA201202967B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ767139A (en) 2009-12-04 2022-08-26 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
WO2014053450A1 (de) 2012-10-02 2014-04-10 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
PL3589638T3 (pl) 2017-03-02 2021-09-27 Eli Lilly And Company Związki użyteczne do hamowania ror-gamma-t
EP3589637B1 (en) * 2017-03-02 2021-04-14 Eli Lilly and Company Compounds useful for inhibiting ror-gamma-t
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
EP3752508A1 (en) 2018-02-16 2020-12-23 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
AR123355A1 (es) 2020-08-26 2022-11-23 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
US20250171459A1 (en) * 2022-02-08 2025-05-29 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
WO2005066183A1 (de) 2003-12-23 2005-07-21 Grünenthal GmbH Spirocyclische cyclohexan-derivate mit affinität zum orl1-rezeptor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
AU1948601A (en) 1999-12-06 2001-06-12 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
ATE403429T1 (de) 2001-04-18 2008-08-15 Euro Celtique Sa Spiropyrazol-verbindungen
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
ATE396995T1 (de) 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
JP2005519921A (ja) * 2002-01-28 2005-07-07 ファイザー株式会社 Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物
JPWO2003095427A1 (ja) 2002-05-10 2005-09-15 大正製薬株式会社 スピロ環化合物
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
MXPA05002622A (es) 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
BRPI0509307A (pt) * 2004-03-29 2007-09-04 Pfizer compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
PT2260042E (pt) 2008-03-27 2011-12-06 Gruenenthal Gmbh Derivados de ciclo-hexano espirocíclicos substituídos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
WO2005066183A1 (de) 2003-12-23 2005-07-21 Grünenthal GmbH Spirocyclische cyclohexan-derivate mit affinität zum orl1-rezeptor

Also Published As

Publication number Publication date
MY160665A (en) 2017-03-15
RS53018B (sr) 2014-04-30
EP2501703B1 (en) 2013-09-18
CA2796161A1 (en) 2011-05-19
NZ600006A (en) 2014-05-30
PL2501703T3 (pl) 2014-02-28
ME01537B (me) 2014-04-20
CN102612520A (zh) 2012-07-25
MA33751B1 (fr) 2012-11-01
CO6541545A2 (es) 2012-10-16
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
HK1169988A1 (en) 2013-02-15
DK2501703T3 (da) 2013-10-14
PE20121430A1 (es) 2012-10-26
DOP2012000135A (es) 2012-08-15
CN102612520B (zh) 2015-04-08
IL219370A0 (en) 2012-06-28
CA2796161C (en) 2015-03-17
JP2013510859A (ja) 2013-03-28
US8232289B2 (en) 2012-07-31
UA107943C2 (xx) 2015-03-10
EP2501703A1 (en) 2012-09-26
MX2012005691A (es) 2012-06-13
EA201290352A1 (ru) 2012-10-30
SI2501703T1 (sl) 2013-11-29
AU2010319581C1 (en) 2014-05-15
CR20130087A (es) 2013-04-17
EA020848B1 (ru) 2015-02-27
IL219370A (en) 2015-01-29
KR20130026523A (ko) 2013-03-13
HRP20130967T1 (hr) 2013-11-22
WO2011060035A1 (en) 2011-05-19
PH12012500969A1 (en) 2013-01-07
PT2501703E (pt) 2013-11-26
ES2435814T3 (es) 2013-12-23
AU2010319581B2 (en) 2013-12-19
US20110118251A1 (en) 2011-05-19
AU2010319581A1 (en) 2012-06-07
TW201127841A (en) 2011-08-16
HN2012001011A (es) 2015-08-31
JP5680101B2 (ja) 2015-03-04
JO2887B1 (en) 2015-03-15
ECSP12011902A (es) 2012-07-31
AR078863A1 (es) 2011-12-07

Similar Documents

Publication Publication Date Title
KR101363830B1 (ko) Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물
KR101368130B1 (ko) Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물
CN106061969B (zh) Trpa1调节剂
CN109526220A (zh) 用于治疗疼痛和疼痛相关的状况的四氢嘧啶并二氮杂*和四氢吡啶并二氮杂*化合物
TW200533656A (en) Therapeutic agents
US20240417407A1 (en) Furoindazole derivatives as gpr84 antagonists
HK1169988B (en) Spiropiperidine compounds as orl-1 receptor antagonists
BR112012012150A2 (pt) compostos spiro piperidina como antagonistas de recep-tor orl-1

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180130

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190125

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210211

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210211